Bicara Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Bicara Therapeutics Inc. (BCAX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BCAX insiders buying or selling?
In the last 12 months, Bicara Therapeutics Inc. insiders reported 1 open-market purchase ($4.8M) and 38 sales ($11.4M) — net selling of $6.6M. Since September 2024, Trabud has recorded 45 Form 4 filings for BCAX: 3 buys ($39.1M) and 42 sells ($13.3M).
Source: SEC EDGAR Form 4
Key Statistics (September 2024 – Sep 10, 2026)
Total Form 4 filings
45
SEC EDGAR
Insider filers
7
Insider buys (3)
$39.1M
Insider sells (42)
$13.3M
Insider sentiment
Net buyingNet insider flow of $25.8M in net buying since September 2024, and $6.6M in net selling over the last 12 months.
Recent BCAX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Ryan Cohlhepp | President, COO & Interim CEO | Sale | 17.5K | $22.90 | $400.7K | SEC ↗ |
| Aug 12, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 12.5K | $27.97 | $349.6K | SEC ↗ |
| Aug 12, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 10.0K | $27.98 | $279.8K | SEC ↗ |
| Aug 12, 2026 | Ryan Cohlhepp | President and COO | Sale | 18.8K | $27.98 | $524.5K | SEC ↗ |
| Jul 14, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 10.0K | $28.42 | $284.2K | SEC ↗ |
| May 26, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 9.2K | $20.42 | $187.9K | SEC ↗ |
| May 20, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 15.0K | $20.04 | $300.6K | SEC ↗ |
| May 18, 2026 | Ryan Cohlhepp | President and COO | Sale | 12.5K | $20.29 | $253.6K | SEC ↗ |
| Apr 28, 2026 | David Raben | Chief Medical Officer | Sale | 5.5K | $22.88 | $125.8K | SEC ↗ |
| Apr 22, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 9.2K | $23.00 | $211.6K | SEC ↗ |
| Apr 20, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 15.0K | $23.61 | $354.1K | SEC ↗ |
| Apr 17, 2026 | Ryan Cohlhepp | President and COO | Sale | 12.5K | $23.01 | $287.6K | SEC ↗ |
| Mar 26, 2026 | David Raben | Chief Medical Officer | Sale | 5.5K | $18.95 | $104.2K | SEC ↗ |
| Mar 24, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 9.2K | $18.52 | $170.3K | SEC ↗ |
| Mar 20, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 15.0K | $18.82 | $282.4K | SEC ↗ |
| Mar 17, 2026 | Ryan Cohlhepp | President and COO | Sale | 12.5K | $19.66 | $245.7K | SEC ↗ |
| Mar 11, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 36.8K | $19.17 | $704.7K | SEC ↗ |
| Mar 7, 2026 | Claire Mazumdar | Chief Executive Officer | Sale | 8.2K | $18.74 | $154.3K | SEC ↗ |
| Mar 6, 2026 | Ryan Cohlhepp | President and COO | Sale | 17.4K | $18.16 | $315.9K | SEC ↗ |
| Mar 6, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 16.5K | $18.22 | $301.0K | SEC ↗ |
| Mar 6, 2026 | David Raben | Chief Medical Officer | Sale | 16.5K | $18.52 | $305.6K | SEC ↗ |
| Mar 2, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 300.0K | $16.00 | $4.8M | SEC ↗ |
| Feb 27, 2026 | Ryan Cohlhepp | President and COO | Sale | 3.6K | $18.04 | $65.5K | SEC ↗ |
| Jan 26, 2026 | Ryan Cohlhepp | President and COO | Sale | 3.8K | $18.10 | $69.3K | SEC ↗ |
| Jan 26, 2026 | Ivan Hyep | Chief Financial Officer | Sale | 1.9K | $18.15 | $34.2K | SEC ↗ |
Showing the 25 most recent of 45 Form 4 filings for Bicara Therapeutics Inc..
Most active BCAX insiders
- Ryan Cohlhepp13 filings
- Claire Mazumdar10 filings
- Ivan Hyep10 filings
- David Raben5 filings
- Lara Meisner4 filings
Ask anything about BCAX insider activity
Use Trabud's AI agent to query Bicara Therapeutics Inc.'s Form 4 history in plain English — "Show me BCAX CEO purchases this year" or compare it against any other ticker.
Open the AI agentBCAX insider trading FAQ
Are Bicara Therapeutics Inc. insiders buying or selling?
In the last 12 months, Bicara Therapeutics Inc. insiders reported 1 open-market purchase ($4.8M) and 38 sales ($11.4M) — net selling of $6.6M. Since September 2024, Trabud has recorded 45 Form 4 filings for BCAX: 3 buys ($39.1M) and 42 sells ($13.3M). Over the full record that is net buying of $25.8M.
How many insiders trade BCAX stock?
7 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Bicara Therapeutics Inc.. The most recent filing was accepted on Sep 10, 2026.
Where does Trabud get BCAX insider trading data?
All BCAX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.